Headache News and Research

Latest Headache News and Research

Top-line results in Pfizer's Lyrica long term safety study for Generalized Anxiety Disorder

Pfizer Inc. announced today that top-line results for Lyrica (pregabalin) capsules Study A0081147 - Long Term Safety and Efficacy of Pregabalin in Subjects with Generalized Anxiety Disorder (GAD) - demonstrate that drug discontinuation symptoms were low after tapering Lyrica treatment following three months and six months in GAD patients.

23 Jul 2012

Computerized mobilization eases chronic neck pain

Computerized mobilization of the cervical spine appears to be a viable treatment option for patients with chronic neck pain, a proof-of-concept trial shows.

17 Jul 2012

Ferring Pharmaceuticals receives FDA approval for new colon-cleansing drug

On July 16, the U.S. Food and Drug Administration approved Prepopik (sodium picosulfate, magnesium oxide and citric acid) to help cleanse the colon in adults preparing for colonoscopy.

17 Jul 2012

U.S. FDA approves Gilead’s Truvada to minimize risk of sexually-acquired HIV infection

Today, the U.S. Food and Drug Administration approved Truvada (emtricitabine/tenofovir disoproxil fumarate), the first drug approved to reduce the risk of HIV infection in uninfected individuals who are at high risk of HIV infection and who may engage in sexual activity with HIV-infected partners. Truto reduce the risk of sexually-acquired HIV infection in adults at high risk.

17 Jul 2012

Gilead receives FDA approval for Truvada to reduce risk of sexually acquired HIV-1 infection

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved once-daily oral Truvada (emtricitabine and tenofovir disoproxil fumarate), in combination with safer sex practices, to reduce the risk of sexually acquired HIV-1 infection in adults at high risk.

17 Jul 2012

Merck to present results from clinical studies on BACE inhibitors at AAIC 2012

Merck, known as MSD outside the United States and Canada, announced today presentations at the upcoming Alzheimer's Association International Conference (AAIC) being held in Vancouver, British Columbia, Canada on July 14-19, 2012.

16 Jul 2012

UCB’s Neupro now available in U.S. pharmacies

UCB announced today that Neupro (Rotigotine Transdermal System) is now available in U.S. pharmacies. Neupro was approved by the U.S Food and Drug Administration in April to treat the signs and symptoms of early and advanced stage idiopathic Parkinson's disease and moderate-to-severe primary Restless Legs Syndrome.

16 Jul 2012

Migraine involves multiple symptoms that vary widely among sufferers

Almost everyone suffers from headache pain occasionally, but for 36 million Americans, intense, debilitating headaches accompanied by other neurological symptoms — also known as migraine syndrome — are a source of physical misery that can have a devastating effect on their quality of life. It is estimated that the medical expenses and loss of productivity caused by migraine costs Americans $20 billion annually.

14 Jul 2012

Arena files lorcaserin hydrochloride MAA with Swissmedic

Arena Pharmaceuticals, Inc. announced today the filing with the Swiss health authority, Swissmedic, of a Marketing Authorization Application (MAA) for lorcaserin hydrochloride, an investigational drug candidate in Switzerland.

12 Jul 2012

Home-based immunoglobulin therapy acceptable in primary immunodeficiency

Subcutaneous immunoglobulin therapy, administered at home, is an acceptable substitute for hospital-based intravenous immunoglobulin in patients with immune deficiencies, according to recent findings published in the Journal of Clinical Immunology.

9 Jul 2012

State roundup: Calif., Oregon grappling with insurance rate increases; Kansas (almost) ready to launch health info network

California Insurance Commissioner Dave Jones denied Blue Shield of California's plan to close several of its health policies to new customers, saying it violated state rules designed to protect consumers from large rate increases. ... Blue Shield, a nonprofit insurer with 3.3 million members statewide, had proposed closing off new enrollment on 22 health plans with about 152,000 customers.

6 Jul 2012

Safety tips to prevent heatstroke during hot weather

People across the country are experiencing sweltering weather with temperatures and the heat index reaching well into the 100-degree range. While many will take refuge in air-conditioned homes or at a local lake or pool, it's important to remember that the heat can be much more than bothersome. It can put your health at risk and even prove life threatening.

3 Jul 2012

More than 40,000 student athletes in Arizona receive Mayo Clinic baseline concussion testing

More than 40,000 student athletes in Arizona have taken advantage of computerized baseline concussion evaluations offered by Mayo Clinic in the program's first year. That amounts to nearly 40 percent of the state's roughly 100,000 high school athletes. Baseline concussion evaluations measure how the brain is working before injury, and are mandatory tests for professional and college athletes.

29 Jun 2012

Arena receives FDA approval for Belviq to treat obesity

The U.S. Food and Drug Administration today approved Belviq (lorcaserin hydrochloride), as an addition to a reduced-calorie diet and exercise, for chronic weight management.

28 Jun 2012

Registry proves invaluable for fibromuscular dysplasia patients

A patient registry is proving invaluable in cataloging the clinical features, symptoms, severity, and outcomes of fibromuscular dysplasia (FMD), a non-inflammatory vascular disease that can cause narrowing of arteries in the carotid (neck) and renal (kidney) arteries, which can result in headache, strokes, and aneurysms.

27 Jun 2012

Patient registry yields new data that is crucial for early diagnosis and treatment of FMD

27 Jun 2012

FDA approves Baxter's GAMMAGARD LIQUID for multifocal motor neuropathy

Baxter International Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved GAMMAGARD LIQUID 10% [Immune Globulin Infusion (Human)] as a treatment for multifocal motor neuropathy (MMN). This is the first immunoglobulin treatment approved for MMN patients in the United States, and it was approved for use with MMN patients in Europe in 2011.

From Baxter International Inc. 25 Jun 2012

Genentech's Perjeta helps people with HER2-positive metastatic breast cancer live longer

Genentech, a member of the Roche Group, announced today that people with HER2-positive metastatic breast cancer (mBC) lived significantly longer (overall survival) when treated with the combination of Perjeta (pertuzumab), Herceptin (trastuzumab) and docetaxel chemotherapy, compared to Herceptin and docetaxel chemotherapy alone in the Phase III CLEOPATRA study.

23 Jun 2012

Iroko announces results from diclofenac Phase 3 study on post-surgical pain

Iroko Pharmaceuticals, LLC today announced Phase 3 study results that showed patients treated with the company's novel, submicron particle, lower-dose diclofenac (18mg and 35mg), a non-steroidal anti-inflammatory drug (NSAID), experienced significant pain relief post surgery compared with placebo>0.01 and P<0.001 respectively).

22 Jun 2012

Data from MAP Pharmaceuticals’ LEVADEX clinical studies to be presented at AHS meeting

MAP Pharmaceuticals, Inc. today announced that the Company will present data on LEVADEX (formerly MAP0004), an orally inhaled investigational drug for the acute treatment of migraine, at the 54th Annual Scientific Meeting of the American Headache Society (AHS) in Los Angeles, CA, June 21-24, 2012.

22 Jun 2012

Headache News and Research

Latest Headache News and Research

Top-line results in Pfizer's Lyrica long term safety study for Generalized Anxiety Disorder

Computerized mobilization eases chronic neck pain

Ferring Pharmaceuticals receives FDA approval for new colon-cleansing drug

U.S. FDA approves Gilead’s Truvada to minimize risk of sexually-acquired HIV infection

Gilead receives FDA approval for Truvada to reduce risk of sexually acquired HIV-1 infection

Merck to present results from clinical studies on BACE inhibitors at AAIC 2012

UCB’s Neupro now available in U.S. pharmacies

Migraine involves multiple symptoms that vary widely among sufferers

Arena files lorcaserin hydrochloride MAA with Swissmedic

Home-based immunoglobulin therapy acceptable in primary immunodeficiency

State roundup: Calif., Oregon grappling with insurance rate increases; Kansas (almost) ready to launch health info network

Safety tips to prevent heatstroke during hot weather

More than 40,000 student athletes in Arizona receive Mayo Clinic baseline concussion testing

Arena receives FDA approval for Belviq to treat obesity

Registry proves invaluable for fibromuscular dysplasia patients

Patient registry yields new data that is crucial for early diagnosis and treatment of FMD

FDA approves Baxter's GAMMAGARD LIQUID for multifocal motor neuropathy

Genentech's Perjeta helps people with HER2-positive metastatic breast cancer live longer

Iroko announces results from diclofenac Phase 3 study on post-surgical pain

Data from MAP Pharmaceuticals’ LEVADEX clinical studies to be presented at AHS meeting

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Headache News and Research

Latest Headache News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in